These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 37892033)

  • 21. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment.
    Seto WK; Liu K; Wong DK; Fung J; Huang FY; Hung IF; Lai CL; Yuen MF
    J Hepatol; 2013 Oct; 59(4):709-16. PubMed ID: 23792029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical efficacy analysis of TMF for the treatment of hyperviremia HBeAg-positive chronic hepatitis B patients with incomplete response to first-line oral antiviral nucleos(t)ide analogues].
    Sheng QJ; Han C; Li YW; Zhang C; Dou XG; Ding Y
    Zhonghua Gan Zang Bing Za Zhi; 2023 Mar; 31(3):252-257. PubMed ID: 37137850
    [No Abstract]   [Full Text] [Related]  

  • 23. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
    Ogawa E; Nomura H; Nakamuta M; Furusyo N; Koyanagi T; Dohmen K; Ooho A; Satoh T; Kawano A; Kajiwara E; Takahashi K; Azuma K; Kato M; Shimoda S; Hayashi J;
    Liver Int; 2020 Jul; 40(7):1578-1589. PubMed ID: 32304611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues.
    Hosaka T; Suzuki F; Kobayashi M; Fujiyama S; Kawamura Y; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    Aliment Pharmacol Ther; 2019 Feb; 49(4):457-471. PubMed ID: 30663078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching to Tenofovir Alafenamide Fumarate in Chronic Hepatitis B Patients Who Had Detectable HBV DNA during Treatment with Entecavir.
    Sato K; Inoue J; Akahane T; Kobayashi T; Takai S; Nakamura T; Sato T; Kimura O; Ninomiya M; Iwata T; Sano A; Tsuruoka M; Onuki M; Sawahashi S; Niitsuma H; Masamune A
    Tohoku J Exp Med; 2022 Nov; 258(4):277-285. PubMed ID: 36244758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Serum Hepatitis B Virus RNA With Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy.
    Liu S; Deng R; Zhou B; Liang X; Liu Z; Peng J; Chen J; Zhou Y; Guo Y; Chen Y; Li W; Shen S; Lu X; Zhao S; Liao X; Liang H; Lan Y; Hou J; Fan R; Sun J
    J Infect Dis; 2022 Sep; 226(5):881-890. PubMed ID: 34931674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
    European Association for the Study of the Liver
    J Hepatol; 2017 Aug; 67(2):370-398. PubMed ID: 28427875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma.
    Baran B
    World J Hepatol; 2015 Jul; 7(13):1742-54. PubMed ID: 26167247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation.
    Hu Z; Zeng H; Hou J; Wang J; Xu L; Zhang Y; Chen M; Zhou Z
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.
    Li J; Hu C; Chen Y; Zhang R; Fu S; Zhou M; Gao Z; Fu M; Yan T; Yang Y; Li J; Liu J; Chen T; Zhao Y; He Y
    BMC Infect Dis; 2021 Jun; 21(1):567. PubMed ID: 34126939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analogues.
    Buti M; Roade L; Riveiro-Barciela M; Esteban R
    Liver Int; 2020 Feb; 40 Suppl 1():15-21. PubMed ID: 32077604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis B virus core-related antigen (HBcrAg) as a prognostic marker for the development of hepatocellular carcinoma: A mini systematic review of the literature.
    Afifi AM; Elgenidy A; Hashim M; Awad AK; Jalal PK
    Rev Med Virol; 2022 Nov; 32(6):e2353. PubMed ID: 35441759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of preoperative antiviral therapy on the prognosis of hepatitis B virus-related hepatocellular carcinoma.
    Liang Y; Zhong D; Zhang Z; Su Y; Yan S; Lai C; Yao Y; Shi Y; Huang X; Shang J
    BMC Cancer; 2024 Mar; 24(1):291. PubMed ID: 38438842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
    Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma.
    Urata Y; Kubo S; Takemura S; Uenishi T; Kodai S; Shinkawa H; Sakae M; Kaneda K; Ohata K; Nozawa A; Suehiro S
    J Hepatobiliary Pancreat Sci; 2012 Nov; 19(6):685-96. PubMed ID: 22203455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B.
    Roade L; Riveiro-Barciela M; Esteban R; Buti M
    Ther Adv Infect Dis; 2021; 8():2049936120985954. PubMed ID: 33614029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients.
    Kayaaslan B; Akinci E; Ari A; Tufan ZK; Alpat SN; Gunal O; Tosun S; Guner R; Tabak F
    Clin Res Hepatol Gastroenterol; 2018 Feb; 42(1):40-47. PubMed ID: 28757048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.
    Kawaguchi K; Honda M; Ohta H; Terashima T; Shimakami T; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Komura T; Unoura M; Kaneko S
    J Gastroenterol; 2018 Jun; 53(6):740-751. PubMed ID: 28849280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long-term virological response to entecavir therapy: A randomized trial.
    Iida-Ueno A; Enomoto M; Kozuka R; Tamori A; Kawada N
    J Med Virol; 2019 Jul; 91(7):1295-1300. PubMed ID: 30815880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.